Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2021 | Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer (Scientific Reports, (2020), 10, 1, (3470), 10.1038/s41598-020-60409-4) | Moufarrij S; Srivastava A; Gomez S; Hadley M; Palmer E; Austin P.T; Chisholm S; Diab N; Roche K; ANGELA YU-CHEN LIN ; Li J; Zhu W; Lopez-Acevedo M; Villagra A; Chiappinelli K.B. | Scientific Reports | 1 | 1 | |
2020 | Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer | Moufarrij S; Srivastava A; Gomez S; Hadley M; Palmer E; Austin P.T; Chisholm S; Roche K; ANGELA YU-CHEN LIN ; Li J; Zhu W; Lopez-Acevedo M; Villagra A; Chiappinelli K.B. | Scientific Reports | 63 | 45 | |
2015 | Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective | Dominici M; Nichols K; Srivastava A; Weiss D.J; Eldridge P; Cuende N; Deans R.J; Rasko J.E.J; Levine A.D; Turner L; Griffin D.L; O'Donnell L; Forte M; Mason C; Wagena E; Janssen W; Nordon R; Wall D; HONG-NERNG HO ; Ruiz M.A; Wilton S; Horwitz E.M; Gunter K.C. | Cytotherapy | 41 | 38 |